
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT
- About


Avantor Inc (AVTR)


- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)

(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/17/2025: AVTR (1-star) has a low Upturn Star Rating. Not recommended to BUY.
1 Year Target Price $14.4
1 Year Target Price $14.4
6 | Strong Buy |
4 | Buy |
11 | Hold |
0 | Sell |
0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -11.12% | Avg. Invested days 26 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() | ![]() |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 10.08B USD | Price to earnings Ratio 14.63 | 1Y Target Price 14.4 |
Price to earnings Ratio 14.63 | 1Y Target Price 14.4 | ||
Volume (30-day avg) 21 | Beta 0.98 | 52 Weeks Range 10.82 - 24.86 | Updated Date 10/18/2025 |
52 Weeks Range 10.82 - 24.86 | Updated Date 10/18/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 1.01 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 10.31% | Operating Margin (TTM) 7.63% |
Management Effectiveness
Return on Assets (TTM) 3.24% | Return on Equity (TTM) 11.73% |
Valuation
Trailing PE 14.63 | Forward PE 13.93 | Enterprise Value 13180641554 | Price to Sales(TTM) 1.51 |
Enterprise Value 13180641554 | Price to Sales(TTM) 1.51 | ||
Enterprise Value to Revenue 1.98 | Enterprise Value to EBITDA 9.34 | Shares Outstanding 681738675 | Shares Floating 663945296 |
Shares Outstanding 681738675 | Shares Floating 663945296 | ||
Percent Insiders 1.37 | Percent Institutions 105.97 |
Upturn AI SWOT
Avantor Inc

Company Overview
History and Background
Avantor, Inc., traces its roots back to 1904. Originally focused on laboratory equipment, it has evolved into a leading global provider of products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. Key milestones include strategic acquisitions that expanded its product portfolio and global reach.
Core Business Areas
- Materials and Consumables: Offers a wide range of high-purity chemicals, lab consumables, customized solutions, and single-use technologies vital for research, development, and manufacturing processes.
- Equipment and Instrumentation: Provides laboratory and production equipment, instruments, and related services, including maintenance, repair, and calibration.
- Services and Solutions: Offers a range of services, including laboratory and process design, validation, and sourcing solutions, aiding customers in improving productivity and efficiency.
Leadership and Structure
Avantor is led by a team of experienced executives and operates with a global structure. Michael Stubblefield is the President and CEO. The company has a board of directors that provides oversight and strategic guidance.
Top Products and Market Share
Key Offerings
- Single-Use Solutions: Single-use technologies are used in biopharmaceutical manufacturing processes, offering flexibility and reduced contamination risk. Competitors include Thermo Fisher Scientific and Sartorius. Market share data is difficult to pinpoint precisely but Avantor is a top player in this segment with estimated revenue in the billions.
- High-Purity Chemicals: Manufactures and distributes high-purity chemicals used in research and manufacturing. Competitors include Merck KGaA and Honeywell. Market share data is difficult to pinpoint precisely but Avantor is a top player in this segment with estimated revenue in the hundreds of millions.
- Lab Products: Distributes a wide range of lab products (e.g. filtration) used in research and manufacturing. Competitors include Thermo Fisher Scientific and VWR. Market share data is difficult to pinpoint precisely but Avantor is a top player in this segment with estimated revenue in the hundreds of millions.
Market Dynamics
Industry Overview
The life sciences and advanced technologies industries are experiencing growth driven by increasing R&D spending, demand for biopharmaceuticals, and advancements in materials science. The industry is competitive and highly regulated.
Positioning
Avantor is positioned as a leading global provider of solutions to the life sciences and advanced technologies industries. Its competitive advantage lies in its broad product portfolio, global reach, and ability to provide customized solutions.
Total Addressable Market (TAM)
The TAM for the life sciences and advanced technologies market is substantial, estimated in the hundreds of billions of dollars. Avantor is well-positioned to capture a significant share of this market through its diverse offerings and strategic partnerships.
Upturn SWOT Analysis
Strengths
- Global Reach
- Broad Product Portfolio
- Strong Customer Relationships
- Customized Solutions
- Strategic Acquisitions
Weaknesses
- High Debt Levels
- Exposure to Economic Cycles
- Integration Risks from Acquisitions
- Dependence on Key Suppliers
Opportunities
- Growing Demand for Biopharmaceuticals
- Expansion in Emerging Markets
- Increasing R&D Spending
- Digital Transformation
- Strategic Partnerships
Threats
- Intense Competition
- Regulatory Changes
- Economic Downturns
- Supply Chain Disruptions
- Rising Raw Material Costs
Competitors and Market Share
Key Competitors
- TMO
- DHR
- SYK
- BIO
Competitive Landscape
Avantor competes with larger, more diversified companies. Its competitive advantage lies in its focus on specific customer segments and its ability to provide customized solutions. Disadvantages include smaller scale and higher debt levels.
Major Acquisitions
Masterflex
- Year: 2021
- Acquisition Price (USD millions): 2300
- Strategic Rationale: Expanding Avantor's single-use and fluid handling offerings, enhancing its biopharma capabilities.
Growth Trajectory and Initiatives
Historical Growth: Analyze historical revenue growth and profit margins over the past years. Refer to publicly available financials, including SEC filings (10-K, 10-Q).
Future Projections: Future projections are based on analyst estimates and industry trends. Refer to analyst reports from reputable financial institutions.
Recent Initiatives: Strategic initiatives include acquisitions, expansion of manufacturing capacity, and investment in R&D.
Summary
Avantor is a key player in the life sciences and advanced technologies industries, offering a diverse product portfolio and customized solutions. Its strategic acquisitions and global reach provide a strong foundation for future growth. However, the company faces challenges, including high debt levels and intense competition. Focus on integration and innovation will be key to sustained success.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings (10-K, 10-Q)
- Company Website
- Analyst Reports
- Industry Research Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market share data is based on estimates and may not be precise. Past performance is not indicative of future results.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Avantor Inc
Exchange NYSE | Headquaters Radnor, PA, United States | ||
IPO Launch date 2019-05-17 | President & CEO Mr. Emmanuel Ligner | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 13500 | Website https://www.avantorsciences.com |
Full time employees 13500 | Website https://www.avantorsciences.com |
Avantor, Inc. engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, and fluid handling tips. It also provides equipment and instrumentation products, including filtration systems, virus inactivation systems, incubators, analytical instruments, evaporators, ultra-low-temperature freezers, biological safety cabinets, peristaltic pumps, and critical environment supplies. In addition, the company offers services and specialty procurements comprising onsite lab and production, equipment, procurement and sourcing, and biopharmaceutical material scale-up and development services. Further, it provides scientific research support services, such as DNA extraction, bioreactor servicing, clinical and biorepository, compound management, cleanroom control, monitoring, maintenance, and sanitization services. The company was founded in 1904 and is headquartered in Radnor, Pennsylvania.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.